Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

Paul Morgan, Piet H. van der Graaf, John Arrowsmith et al. · Drug Discovery Today · 2011 · 677 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

Arup K. Ghose, Torsten Herbertz, Robert L. Hudkins et al. · ACS Chemical Neuroscience · 2011 · 437 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery

J. Cory Kalvass, Tristan S. Maurer · Biopharmaceutics & Drug Disposition · 2002 · 415 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 369 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance

Frank Boess, Martin Hendrix, F. Josef van der Staay et al. · Neuropharmacology · 2004 · 325 citations

Life Sciences, Neurobiology, Neuroscience +15